Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Collections
      • Disparities Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Collections
      • Disparities Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Null Results in Brief

Psychotropic medication use and postmenopausal breast cancer risk

Anna George, Susan R Sturgeon, Susan E. Hankinson, Aladdin H. Shadyab, Robert B Wallace and Katherine W. Reeves
Anna George
Department of Biostatistics and Epidemiology, University of Massachusetts Amherst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna George
Susan R Sturgeon
Department of Biostatistics and Epidemiology, University of Massachusetts Amherst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan E. Hankinson
Department of Biostatistics and Epidemiology, University of Massachusetts Amherst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aladdin H. Shadyab
Family Medicine and Public Health, University of California - San Diego School of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert B Wallace
Department of Epidemiology, University of Iowa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine W. Reeves
Department of Biostatistics and Epidemiology, University of Massachusetts Amherst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kwreeves@schoolph.umass.edu
DOI: 10.1158/1055-9965.EPI-19-0776
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background Prior studies evaluating psychotropic medications in relation to breast cancer risk are inconsistent and have not separately evaluated invasive and in situ disease. Methods We estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association of psychotropic medication use (any, typical antipsychotics, atypical antipsychotics, lithium) with invasive and in situ breast cancer risk among Women's Health Initiative participants (N=155,737). Results Prevalence of psychotropic medication use was low (n=642; 0.4%). During an average 14.8 (SD 6.5) years of follow-up, 10,067 invasive and 2,285 in situ breast were diagnosed. Any psychotropic medication use was not associated with invasive breast cancer risk compared to non-users (HR 0.82, 95% CI 0.57-1.18). In situ breast cancer risk was higher among "typical" antipsychotic medication users compared with non-users (HR 2.05, 95% CI 0.97-4.30). Conclusions Findings do not support an association of psychotropic medication use with invasive breast cancer risk. The possible elevation in in situ breast cancer risk associated with "typical" antipsychotics could not be explained by differences in screening mammography utilization and merits further study. Impact Our findings contribute to knowledge of the safety profile of psychotropic medications and may be useful to clinicians and patients considering use of these medications.

  • Received July 29, 2019.
  • Revision received August 30, 2019.
  • Accepted October 29, 2019.
  • Copyright ©2019, American Association for Cancer Research.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't.
PreviousNext
Back to top

Published OnlineFirst November 4, 2019
doi: 10.1158/1055-9965.EPI-19-0776

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Psychotropic medication use and postmenopausal breast cancer risk
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
Citation Tools
Psychotropic medication use and postmenopausal breast cancer risk
Anna George, Susan R Sturgeon, Susan E. Hankinson, Aladdin H. Shadyab, Robert B Wallace and Katherine W. Reeves
Cancer Epidemiol Biomarkers Prev November 4 2019 DOI: 10.1158/1055-9965.EPI-19-0776

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Psychotropic medication use and postmenopausal breast cancer risk
Anna George, Susan R Sturgeon, Susan E. Hankinson, Aladdin H. Shadyab, Robert B Wallace and Katherine W. Reeves
Cancer Epidemiol Biomarkers Prev November 4 2019 DOI: 10.1158/1055-9965.EPI-19-0776
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Genetic Variants and Colorectal Cancer Survival
  • Statin Use and Prostate Cancer Incidence in Manitoba, Canada
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement